Show Notes
- Amazon USA Store: https://www.amazon.com/dp/B078VW3VM7?tag=9natree-20
- Amazon Worldwide Store: https://global.buys.trade/Bad-Blood%3A-Secrets-and-Lies-in-a-Silicon-Valley-Startup-John-Carreyrou.html
- Apple Books: https://books.apple.com/us/audiobook/bad-blood-secrets-and-lies-in-a-silicon-valley/id1417742027?itsct=books_box_link&itscg=30200&ls=1&at=1001l3bAw&ct=9natree
- eBay: https://www.ebay.com/sch/i.html?_nkw=Bad+Blood+Secrets+and+Lies+in+a+Silicon+Valley+Startup+John+Carreyrou+&mkcid=1&mkrid=711-53200-19255-0&siteid=0&campid=5339060787&customid=9natree&toolid=10001&mkevt=1
- Read more: https://english.9natree.com/read/B078VW3VM7/
#Theranos #corporatefraud #startupculture #businessethics #investigativejournalism #BadBlood
Bad Blood: Secrets and Lies in a Silicon Valley Startup by investigative reporter John Carreyrou is a nonfiction exposé of Theranos, the Silicon Valley health technology company founded by Elizabeth Holmes. The book traces how Theranos rose from an audacious promise to revolutionize blood testing to a multibillion dollar valuation, and how that promise unraveled under scrutiny. Carreyrou, known for his reporting at The Wall Street Journal, reconstructs the story through extensive interviews and documentary reporting, showing how bold claims about proprietary devices and tiny blood samples collided with scientific and operational reality. Beyond the headline scandal, the book examines the forces that sustained the deception: secrecy inside the company, a culture of fear, high profile supporters, and a startup ecosystem that often rewards vision and momentum more than verification. Written with the pace of a thriller but grounded in reporting, it serves as both a narrative of a corporate collapse and a cautionary study in ethics, oversight, and accountability in health related innovation.
Bad Blood is best suited for readers interested in business ethics, startup culture, corporate governance, health technology, and the craft of investigative reporting. It offers practical benefits for entrepreneurs and executives by illustrating how credibility is built and lost, and why transparency, validation, and a speak up culture are not optional in high stakes industries. Investors and managers can use its lessons as a checklist for due diligence: demand evidence, understand the limits of secrecy, and distinguish visionary storytelling from verifiable performance. For readers in health care or policy, the book clarifies why diagnostic testing requires rigorous oversight and why regulatory and institutional guardrails matter when innovation directly affects patients. What makes Carreyrous work stand out among corporate scandal books is the combination of narrative drive and methodical reporting. It does not rely on sensationalism alone; it shows how ordinary incentives, deference to prestige, and fear inside organizations can produce extraordinary failures. Compared with broader Silicon Valley critiques, it remains unusually concrete, grounded in the lived details of a single company and the steps by which its claims were tested and ultimately challenged. The result is a cautionary, readable account of how fraud can masquerade as innovation until reality intervenes.